N6-methyladenosine regulators in hepatocellular carcinoma: investigating the precise definition and clinical applications of biomarkers
Our findings suggest that the mutual validation of big data analysis and functional experiments may facilitate the precise identification and definition of biomarkers, and our m6A risk models may have the potential to guide personalized chemotherapy, targeted treatment, and immunotherapy decisions in HCC.
Authors
- Lulu Yin (ORCID: https://orcid.org/0000-0003-2932-6349)
- Xinyue Yao (ORCID: https://orcid.org/0000-0002-8378-0545)
- Guoqiang Wan (ORCID: https://orcid.org/0000-0003-3841-9301)
- Jie Ying Fu (ORCID: https://orcid.org/0000-0002-5489-2732)
- Xiao Liu (ORCID: https://orcid.org/0000-0001-8400-5754)
- Nanjing Zhou
- Hao Wang (ORCID: https://orcid.org/0000-0003-2131-0377)
- Yao Qi
- Yingchun Gao
- Xinxin Ye (ORCID: https://orcid.org/0009-0001-8870-6758)
- Xiaokai Yan (ORCID: https://orcid.org/0000-0002-8507-3473)
- Xing Chen (ORCID: https://orcid.org/0000-0002-8630-1589)
Institutions
- Zunyi Medical University (CN)
- Zhejiang Cancer Hospital (CN)
- National Engineering Research Center for Nanotechnology (CN)
Publication Details
- Journal
- Biology Direct
- Published
- 2024-11-07
- DOI
- https://doi.org/10.1186/s13062-024-00554-2
- Citations
- 2
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Natural Science Foundation of Guizhou Province
- Natural Science Foundation of Zhejiang Province